Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Proposed Legislation Seeks 12-Year Market Exclusivity for FDA-Approved Botanical Drugs

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at geneonline.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

U.S. lawmakers introduced the Advancing Botanical Drug Development Act of 2026, proposing a 12-year market exclusivity for FDA-approved botanical drugs to incentivize investment by extending exclusive marketing rights.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must rethink your investment timeline if you develop botanical drugs because exclusivity now lasts much longer, reducing generic threats. This opens a window to pitch for longer returns on botanical drug projects.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbotanical-drugsfda-regulationmarket-exclusivitypharma-investmentus-legislation